Guerbet Showcases Ongoing Collaboration with IBM Watson at Radiology Trade Fair

Guerbet has more than 90 years of experience in the contrast-agent field and offers a comprehensive range of pharmaceutical products, medical devices and services for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients.

Watson Imaging Patient Synopsis is a radiologist-trained artificial intelligence (AI) tool that extracts relevant patient information, summarized into tailored, specific, and concise single-view reports to better inform diagnostic decisions. Guerbet demonstrated Patient Synopsis alongside its Digital Services offerings at RSNA 2018. Guerbet, an IBM Business Partner, and IBM are finalizing the terms by which Guerbet will become the first reseller of Patient Synopsis. This planned reseller relationship is in addition to IBM and Guerbet's ongoing efforts to co-develop and distribute innovative, clinical decision support solutions. Earlier this year, Guerbet had signed a joint development agreement with IBM Watson Health to develop an AI software solution supporting liver cancer diagnostics and care which will be a great addition to Guerbet's Digital Services portfolio in the near future.

Guerbet's Contrast & Care is also part of its Digital Services offerings and enables radiology departments to collect, archive, examine and share injection data directly with Guerbet's injectors, advancing data transfer and accuracy in dosing to help radiologists best serve patients. Likewise, at the RSNA 2018, Guerbet displayed Imalogix, a cloud-based performance management and dose monitoring solution already available in the US market.

"We are excited to feature Watson Imaging Patient Synopsis, Contrast & Care and Imalogix at this year's RSNA," said Massimo Carrara, Guerbet Vice President for North America. "Our products and commercial partnerships with cutting-edge Digital Solutions affirm our commitment to offering the 'best of the best' in diagnostic and interventional imaging, and support Guerbet's five-year plan to capture growth opportunities and move toward a new and innovative future of medical imaging."